Vertex Pharmaceuticals and CRISPR Therapeutics Announce Authorization of CASGEVY
Conditional Approval for Both Sickle Cell Disease and Transfusion Dependent Beta Thalassemia
Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) today announced that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) granted them conditional marketing authorization for CASGEVYTM (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene . . .